Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04OTY
|
|||
| Former ID |
DIB001535
|
|||
| Drug Name |
BFH-772
|
|||
| Synonyms |
NVP-BFH-772
Click to Show/Hide
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H16F3N3O3
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=NC=NC(=C4)CO)C(F)(F)F
|
|||
| InChI |
1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)
|
|||
| InChIKey |
JNLSTLQFDDAULK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 890128-81-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor (VEGFR) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health. | |||
| REF 2 | CA patent application no. 841416, Method of selecting therapeutic indications. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.